The new assay meets the necessary quality and regulatory requirements to support GFAP routine testing. Credit: murat photographer / Shutterstock.

HU Group subsidiary Fujirebio has launched the Lumipulse G GFAP assay, a new tool for neurological research, in the US.

The assay, for research use only, is designed for the quantitative glial fibrillary acidic protein (GFAP) measurement.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With the launch of this assay, the company further strengthens its neuro test menu.

The fully automated, random-access Lumipulse G GFAP assay is set to be released in Japan, Europe and other regions as of September 2024.

It enables the measurement of GFAP in human plasma and serum with a turnaround time of just 35 minutes. This assay is expected to advance research into neurological conditions such as multiple sclerosis and Alzheimer’s disease.

See Also:

The Lumipulse G platform allows professionals to measure GFAP in a user-friendly method.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It meets the necessary quality and regulatory requirements to support GFAP routine testing in combination with other tests from the neuro biomarker menu of Fujirebio.

Fujirebio president and CEO Goki Ishikawa said: “In 2023, we already introduced two new important neuro assays for RUO-based detection of neurofilament Light (NfL) and pTau 217.

“We continue our engagement in biomarker-based testing for neurological diseases with the Lumipulse G GFAP, affirming our commitment to play an essential partnering role in both research and clinical routine.”

In April 2023, Fujirebio expanded its fully automated blood-based biomarker portfolio with two completely automated assays for research use only.

The two assays, namely the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE, are intended for the company’s completely automated LUMIPULSE G Systems.

Fujirebio is engaged in offering a range of assays for neurological conditions. The company collaborates globally with experts to innovate in neurodegenerative diagnostic tools.